ALK and non-small cell lung carcinoma: A network meta-analysis by Wang et al. suggested that lorlatinib might prolong PFS compared to brigatinib (HR: 0.57; p=0.03) and alectinib (HR: 0.65; p=0.05) in previously untreated patients with ALK-positive advanced NSCLC [3]. This supports the potential role of lorlatinib as a first-line treatment option, which could potentially delay the emergence of resistance mutations.